EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

Checkpoint inhibitors create rogue regulatory T cells

Smriti Parashar, Klaus Ley

Journal of Clinical Investigation · 01.07.2026 · 136 (13)

DOI: 10.1172/jci206592 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.07.2026. Verfasst von Smriti Parashar und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Immune Checkpoint Inhibitors, Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor–induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) following treatment with PD-1, PD-L1, or CTLA-4 inhibitors in patients with cancer. In this issue of the JCI , Ma and colleagues identified a subset of regulatory T cells (Tregs) that coexpress CD137 and IL-6 receptor (IL6R), termed atypical Tregs (AtpTregs), which are selectively enriched in patients with ICI-IA. Functionally, AtpTregs exhibited reduced suppressive capacity and a Th17-like proinflammatory phenotype. Notably, these cells were associated with more severe arthritis, yet improved cancer outcomes, suggesting a potential role in tumor control. The anti-IL6R therapy tocilizumab, administered as an off-label intervention for ICI-IA, reduced AtpTreg abundance and alleviated arthritis while maintaining antitumor immunity in a small cohort of patients with new-onset ICI-IA. Thus, anti-IL6R could be a targeted approach to manage ICI-IA and potentially other irAEs involving AtpTregs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryImmune Checkpoint InhibitorsNeoplasmsAntibodies, Monoclonal, HumanizedArthritisHumansReceptors, Interleukin-6Animals

Substanzen

Immune Checkpoint InhibitorsReceptors, Interleukin-6Antibodies, Monoclonal, HumanizedIL6R protein, humantocilizumab

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Parashar, S., & Ley, K. (2026). Checkpoint inhibitors create rogue regulatory T cells. Journal of Clinical Investigation, 136(13). https://doi.org/10.1172/jci206592

Vancouver

Parashar S, Ley K. Checkpoint inhibitors create rogue regulatory T cells. Journal of Clinical Investigation. 2026;136(13). doi:10.1172/jci206592

BibTeX
@article{Parashar2026,
  author = {Parashar, Smriti and Ley, Klaus},
  title = {Checkpoint inhibitors create rogue regulatory T cells},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {13},
  doi = {10.1172/jci206592}
}
Kostenlos starten →